Abstract
In Japan, herbal products are available as Kampo medicines (Japanese traditional herbal medicines), non-Kampo medicines (herbal medicines not based on Kampo principles), and herbal products sold as health foods or unlicensed herbal medicines. Although the traditional opinion that herbal products are natural and safe still commonly exists, there is increasing awareness of herbal safety problems following the announcement of the Ministry of Health, Labour and Welfare (MHLW) that the Kampo formula Shosaikoto, a bupleurum (Bupleurum falcatum L.) root product, was associated with interstitial pneumonia and deaths in the late 1990s (Ministry of Health, Labour and Welfare, Pharmaceuticals and Medical Devices Safety Information No. 146). This chapter focuses on current regulations and safety monitoring for herbal products in Japan.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hakamatsuka T (2014) About medicinal products from Western herb. Farumashia 50(10):978–982
Maekawa H, Nakamura T, Saito K (2014) Regulation of traditional herbal medicinal products in Japan. J Ethnopharmacol 158:511–515
Ministry of Health, Labour and Welfare (2019) The list of raw materials exclusively used as pharmaceuticals. https://www.mhlw.go.jp/file/06-Seisakujouhou-11130500-Shokuhinanzenbu/0000086062_1.pdf. Accessed 18 Feb 2020
Ministry of Health, Labour and Welfare (2016) Japanese Pharmacopoeia 17th Edition (with Suppl. 1 & 2). http://www.mhlw.go.jp/topics/bukyoku/iyaku/yakkyoku/english.html. Accessed 18 Feb 2020
Pharmaceutical and Food Safety Bureau (2018) The Japanese standards for non-pharmacopoeial crude drugs
Pharmaceutical and Food Safety Bureau (2017) Approval standards for manufacturing and selling OTC Kampo products
Nagata Y (2012) Essence on the guide to taking Kampo medicines. Kanpoiyakugakuzasshi 20(1):16
National Institutes of Biomedical Innovation, Health and Nutrition (2018) Standards of reporting Kampo products. http://mpdb.nibiohn.go.jp/stork/index.html
Ministry of Health, Labour and Welfare. About health foods. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/hokenkinou/. Accessed 20 Feb 2020
Ministry of Health, Labour and Welfare (2019) The statistics of production by pharmaceutical industry 2018. https://www.mhlw.go.jp/topics/yakuji/2018/nenpo/
Hakamatsuka T (2011) Revision of Kampo extra formulae that recorded in Japanese pharmacopoeia and standard approval for OCT Kampo products. Farumashia 47:413–417
Japan Kampo Medicines Manufacturers Association (2011) Suvery of Kampo medicine for prescription uses. https://www.nikkankyo.org/serv/serv1.htm
Arai I, Sugiyama K (2009) Survey on the views of Kampo formulae. J Jpn Soc Orient Med 59:124
Ministry of Health, Labour and Welfare (1998) Pharmaceuticals and Medical Devices Safety Information No. 146. https://www.pmda.go.jp/safety/info-services/drugs/calling-attention/safety-info/0014.html#1
Tsukiyama K, Tasaka Y, Nakajima M et al (1989) A case of pneumonitis due to sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 27(12):1556–1561
Takada N, Arai S, Kusuhara N et al (1993) A case of sho-saiko-to-induced pneumonitis, diagnosed by lymphocyte stimulation test using bronchoalveolar lavage fluid. Nihon Kyobu Shikkan Gakkai Zasshi 31(9):1163–1169
Hatakeyama S, Tachibana A, Morita M, Suzuki K, Okano H (1997) Five cases of pneumonitis induced by sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 35(5):505–510
Kobashi Y, Nakajima M, Niki Y, Matsushima T (1997) A case of acute eosinophilic pneumonia due to Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 35(12):1372–1377
Suzuki H, Kumada H, Sato K et al (2000) Guidelines of Sho-saiko-to/**ao-Chaihu-Tang treatment in patients with chronic hepatitis C. Wakaniyakugaku Zasshi 17(3):95–100
Mizushima Y, Oosaki R, Kobayashi M (1997) Clinical features of pneumonitis induced by herbal drugs. Phytother Res 11(4):295–298
Oketani N, Saito H, Ebe T (1996) Pneumonitis due to Hangeshashin-to. Nihon Kyobu Shikkan Gakkai Zasshi 34(9):983–988
Maruyama Y, Maruyama M, Takada T, Haraguchi M, Uno K (1994) A case of pneumonitis due to Rikkunshi-to. Nihon Kyobu Shikkan Gakkai Zasshi 32(1):84–89
Ishigawa S, Takuma H (2013) A signal identification methods for detecting side effect of Kampo prescription medicines. In: Conference proceedings of the 133th annual meeting of the Pharmaceutical Society of Japan 2013
Shimodaira H, Nozaki M, Kwon Y, Kamimura N, Kaiho F (2014) Analysis of adverse reaction in Kampo-medicines using JADER database of PMDA. Jpn J Drug Inf 16(1):16–22
Pharmaceutical and Medical Devices Agency (PMDA). http://www.info.pmda.go.jp/index.html. Accessed 18 Feb 2020
Uppsala Monitoring Centre (UMC) WHODrug Global. https://www.who-umc.org/whodrug/whodrug-portfolio/whodrug-global/. Accessed 6 Mar 2020
Uppsala Monitoring Centre (UMC) WHODrug Cross Reference Tool (CRT) Japan. https://www.who-umc.org/whodrug/whodrug-portfolio/whodrug-crt-japan/. Accessed 18 Feb 2020
Matsui K, Iimura Y (2014) Introduction and application of datamining method in safety monitoring. Farumashia 50(6):543–547
Ohmuta M (2017) Make your reports with Medi-navi: drug safety strategy and spontaneous reporting scheme for medicines and medical devices. In: The 50th academic conference of Japan Pharmaceutical Association, Tokyo
Matsui K (2013) Recent activities of drug safety monitoring strategy: a perspective from survey and analysis. Kurume biostatistics forum
Pharmaceuticals and Medical Devices Agency (PMDA). Japanese adverse drug event report database (JADER). http://www.info.pmda.go.jp/fukusayou/menu_fukusayou_new_attention.html. Accessed 18 Feb 2020
Arai I, Harada Y, Koda H, Tsutani K, Motoo Y (2020) Estimated incidence per population of adverse drug reactions to Kampo medicines from the Japanese adverse drug event report database (JADER). Tradit Kampo Med 7:3–16. https://doi.org/10.1002/tkm2.1234
Ministry of Health, Labour and Welfare (2002) Correspondence for preventing health harms from health foods and unlicensed medicines. https://www.mhlw.go.jp/houdou/2002/10/h1004-3.html. Accessed 18 Feb 2020
Pharmaceuticals and Medical Devices Agency (PMDA). Safety information of medicines and medical devices. https://www.pmda.go.jp/safety/info-services/drugs/calling-attention/safety-info/0043.html. Accessed 18 Feb 2020
Japan Kampo Medicines Manufacturers Association (JKMA). Information sheet of OTC Kampo medicines for customers. https://www.nikkankyo.org/seihin/seihin5.htm. Accessed 18 Feb 2020
National Institutes of Biomedical Innovation, Health and Nutrition (NIBIHN). Information system on safety and effectiveness for health foods. https://hfnet.nibiohn.go.jp. Accessed 18 Feb 2020
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Teng, L. (2022). Pharmacovigilance for Herbal and Traditional Medicines in Japan. In: Barnes, J. (eds) Pharmacovigilance for Herbal and Traditional Medicines. Adis, Cham. https://doi.org/10.1007/978-3-031-07275-8_24
Download citation
DOI: https://doi.org/10.1007/978-3-031-07275-8_24
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-031-07273-4
Online ISBN: 978-3-031-07275-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)